Literature DB >> 325016

Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients.

H Teshima, H Wanebo, C Pinsky, N K Day.   

Abstract

The presence of circulating immune complexes in freshly drawn sera of patients with various forms of malignancies was detected by the 125I-Clq deviation test of Sobel et al. More than 50% of the 459 cancer sera showed a high inhibition of 125I-Clq uptake by sensitized sheep erythrocytes when compared with sera of 50 healthy laboratory personnel. The levels were compared with levels of total hemolytic complement and immunochemical determinations of Cl1 and C3. A correlation between high levels of circulating immune complexes and low levels of Clq was suggested. These immune complexes were separated by sucrose density gradient ultracentrifugation at low pH and were found to be heavier than 19S. Fluctuation of levels of immune complexes was evident when serial samples from the same patient were tested. Decrease of levels of immune complexes and a concomitant increase of Clq were detected after Calmette-Gueérin bacillus and autologous tumor cell treatment in some melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 325016      PMCID: PMC372326          DOI: 10.1172/JCI108737

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  MOUSE BETA-1C-GLOBULIN: PRODUCTION OF ANTISERUM AND CHARACTERIZATION IN THE COMPLEMENT REACTION.

Authors:  M R MARDINEY; H J MUELLER-EBERHARD
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

2.  Significance of serum factors modifying cellular immune responses to growing tumours.

Authors:  R W Baldwin; M R Price; R A Robins
Journal:  Br J Cancer Suppl       Date:  1973-08

3.  Cellular and humoral immunity to rat hepatoma-specific antigens correlated with tumour status.

Authors:  R W Baldwin; M J Embleton; R A Robins
Journal:  Int J Cancer       Date:  1973-01-15       Impact factor: 7.396

4.  Precipitin reactions of the C1q component of complement with aggregated gamma-globulin and immune complexes in gel diffusion.

Authors:  V Agnello; R J Winchester; H G Kunkel
Journal:  Immunology       Date:  1970-12       Impact factor: 7.397

5.  An enzymic method for the trace iodination of immunoglobulins and other proteins.

Authors:  J J Marchalonis
Journal:  Biochem J       Date:  1969-06       Impact factor: 3.857

6.  IMMUNOLOGICAL STUDIES OF THE 11S PROTEIN COMPONENT OF THE HUMAN COMPLEMENT SYSTEM.

Authors:  J H MORSE; C L CHRISTIAN
Journal:  J Exp Med       Date:  1964-02-01       Impact factor: 14.307

7.  Evidence for immune complexes involving anti-lymphocyte antibodies associated with hypocomplementaemia in chronic lymphocytic leukaemia (CLL).

Authors:  N K Day; J B Winfield; T Gee; R Winchester; H Teshima; H G Kunkel
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

8.  Crystalline desoxyribonuclease; isolation and general properties; spectrophotometric method for the measurement of desoxyribonuclease activity.

Authors:  M KUNITZ
Journal:  J Gen Physiol       Date:  1950-03       Impact factor: 4.086

9.  An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis.

Authors:  E C FRANKLIN; H R HOLMAN; H J MULLER-EBERHARD; H G KUNKEL
Journal:  J Exp Med       Date:  1957-05-01       Impact factor: 14.307

10.  BCG immunotherapy of a rat sarcoma.

Authors:  R W Baldwin; M V Pimm
Journal:  Br J Cancer       Date:  1973-10       Impact factor: 7.640

View more
  22 in total

1.  Studies on circulating soluble immune complexes of the liver disease. 1. Inhibition assay of polyclonal rheumatoid factor binding to IgG-sepharose.

Authors:  J Narumoto; T Arima; K Kunishi; T Yasuhara; K Suwaki; H Shimomura; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1979-12

2.  Prognostic value of serial determinations of circulating immune complex levels in malignant melanoma.

Authors:  A Bukh; A Møller-Larsen; M T Aguado; F Møller-Larsen; N P Møller
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Quantitation and characterization of soluble immune complexes precipitated from sera by polyethylene glycol (PEG).

Authors:  D Chia; E V Barnett; J Yamagata; D Knutson; C Restivo; D Furst
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

4.  Bovine antigens and the formation of circulating immune complexes in selective immunoglobulin A deficiency.

Authors:  C Cunningham-Rundles; W E Brandeis; R A Good; N K Day
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

5.  Circulating immune complexes in sera of children with neuroblastoma: correlation with stage of disease.

Authors:  W E Brandeis; L Helson; Y Wang; R A Good; N K Day
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

6.  [Circulating immune complexes in bronchogenic carcinoma: relation to extent of disease and to therapy (author's transl)].

Authors:  C Gropp; K Havemann; T Schärfe; H Schultz; E Schaumlöffel
Journal:  Klin Wochenschr       Date:  1979-04-17

7.  Circulating immune complexes in gastric cancer patients and their effect on lymphocyte mitogenesis (the first report).

Authors:  Y Osaki; S Koga; M Maeta; N Shimizu; H Kanayama; R Hamazoe
Journal:  Jpn J Surg       Date:  1984-11

8.  Nature of antigens and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients.

Authors:  R K Gupta; A M Leitch; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Demonstration of IgG Fc receptors on spermatozoa and their utilization for the detection of circulating immune complexes in human serum.

Authors:  S S Witkin; S K Shahani; S Gupta; R A Good; N K Day
Journal:  Clin Exp Immunol       Date:  1980-09       Impact factor: 4.330

10.  Consistent fluctuations in quantities of circulating immune complexes during progressive and regressive phases of tumor growth.

Authors:  J C Jennette
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.